Big Board Alerts

Akari Therapeutics merge with Peak Bio

[[{“value”:”

Akari Therapeutics have merged with Peak Bio, with an expanded pipeline that contains multiple compelling assets, spanning early and late development stages. An assessment of the pipeline is planned, including program prioritisation, updated timelines, near-term value creation opportunities, and other considerations. The combined entity will operate as Akari Therapeutics, Plc.

Key highlights of the merger include a robust ADC toolkit with novel payload and linker technologies, multiple compelling assets spanning early and late stages, strategic focus to emphasise business development and licensing with broad potential impact on patients and proven leadership.

The post-merger Board of Directors will consist of three directors selected by each company and one independent director jointly selected.

“}]] 

Latest Articles

DON’T MISS THE OPPORTUNITY TO JOIN OUR MARKET SUMMARY REPORT FOR A LIMITED TIME

By submitting this form on our website, you agree that we may collect and use your personal information for marketing, and for other purposes as set forth in our privacy policy, which we encourage you to review.